三联疗法：步入转移性激素敏感性前列腺癌治疗的元宇宙 - Suppr

Triplet Therapy: Entering the Metaverse of Metastatic Hormone-sensitive Prostate Cancer Treatment.

作者信息

Dzimitrowicz Hannah E, Armstrong Andrew J

机构信息

Department of Medicine, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC, USA.

出版信息

Eur Urol. 2022 Dec;82(6):599-601. doi: 10.1016/j.eururo.2022.08.031. Epub 2022 Sep 13.

DOI:10.1016/j.eururo.2022.08.031

PMID:36114081

Abstract

摘要

相似文献

Triplet Therapy: Entering the Metaverse of Metastatic Hormone-sensitive Prostate Cancer Treatment.

Eur Urol. 2022 Dec;82(6):599-601. doi: 10.1016/j.eururo.2022.08.031. Epub 2022 Sep 13.

Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer-Calling Out the "Double Standard".

JAMA Oncol. 2023 May 1;9(5):617-619. doi: 10.1001/jamaoncol.2023.0324.

Hormone sensitive protocol for metastatic prostate cancer, an update.

Actas Urol Esp (Engl Ed). 2023 May;47(4):244-249. doi: 10.1016/j.acuroe.2022.10.002. Epub 2022 Oct 18.

Triplet Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.

J Clin Oncol. 2023 Aug 1;41(22):3873-3874. doi: 10.1200/JCO.23.00686. Epub 2023 May 31.

Update on metastatic hormone-sensitive prostate cancer.

Clin Adv Hematol Oncol. 2022 May;20(5):277-280.

Rezvilutamide for metastatic hormone-sensitive prostate cancer.

Lancet Oncol. 2022 Nov;23(11):e490. doi: 10.1016/S1470-2045(22)00624-6.

Treatment options for metastatic hormone-sensitive prostate cancer.

Lancet Oncol. 2022 Oct;23(10):1234-1235. doi: 10.1016/S1470-2045(22)00520-4. Epub 2022 Sep 5.

Rezvilutamide for metastatic hormone-sensitive prostate cancer - Authors' reply.

Lancet Oncol. 2022 Nov;23(11):e491. doi: 10.1016/S1470-2045(22)00630-1.

Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis.

Eur Urol Oncol. 2022 Oct;5(5):494-502. doi: 10.1016/j.euo.2022.06.003. Epub 2022 Jul 8.

Management of Metastatic Hormone-Sensitive Prostate Cancer: Is Docetaxel Needed?

J Clin Oncol. 2022 Nov 1;40(31):3573-3575. doi: 10.1200/JCO.22.00705. Epub 2022 Jun 20.

引用本文的文献

Impact of disease volume on survival efficacy of triplet therapy for metastatic hormone-sensitive prostate cancer: a systematic review, meta-analysis, and network meta-analysis.

Int J Clin Oncol. 2024 Jun;29(6):716-725. doi: 10.1007/s10147-024-02485-4. Epub 2024 Apr 6.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Triplet Therapy: Entering the Metaverse of Metastatic Hormone-sensitive Prostate Cancer Treatment.

作者信息

Dzimitrowicz Hannah E, Armstrong Andrew J

机构信息

Department of Medicine, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC, USA.

出版信息

Eur Urol. 2022 Dec;82(6):599-601. doi: 10.1016/j.eururo.2022.08.031. Epub 2022 Sep 13.

DOI:10.1016/j.eururo.2022.08.031

PMID:36114081

Abstract

摘要

相似文献

Triplet Therapy: Entering the Metaverse of Metastatic Hormone-sensitive Prostate Cancer Treatment.

Eur Urol. 2022 Dec;82(6):599-601. doi: 10.1016/j.eururo.2022.08.031. Epub 2022 Sep 13.

Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer-Calling Out the "Double Standard".

JAMA Oncol. 2023 May 1;9(5):617-619. doi: 10.1001/jamaoncol.2023.0324.

Hormone sensitive protocol for metastatic prostate cancer, an update.

Actas Urol Esp (Engl Ed). 2023 May;47(4):244-249. doi: 10.1016/j.acuroe.2022.10.002. Epub 2022 Oct 18.

Triplet Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.

J Clin Oncol. 2023 Aug 1;41(22):3873-3874. doi: 10.1200/JCO.23.00686. Epub 2023 May 31.

Update on metastatic hormone-sensitive prostate cancer.

Clin Adv Hematol Oncol. 2022 May;20(5):277-280.

Rezvilutamide for metastatic hormone-sensitive prostate cancer.

Lancet Oncol. 2022 Nov;23(11):e490. doi: 10.1016/S1470-2045(22)00624-6.

Treatment options for metastatic hormone-sensitive prostate cancer.

Lancet Oncol. 2022 Oct;23(10):1234-1235. doi: 10.1016/S1470-2045(22)00520-4. Epub 2022 Sep 5.

Rezvilutamide for metastatic hormone-sensitive prostate cancer - Authors' reply.

Lancet Oncol. 2022 Nov;23(11):e491. doi: 10.1016/S1470-2045(22)00630-1.

Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis.

Eur Urol Oncol. 2022 Oct;5(5):494-502. doi: 10.1016/j.euo.2022.06.003. Epub 2022 Jul 8.

Management of Metastatic Hormone-Sensitive Prostate Cancer: Is Docetaxel Needed?

J Clin Oncol. 2022 Nov 1;40(31):3573-3575. doi: 10.1200/JCO.22.00705. Epub 2022 Jun 20.

引用本文的文献

Impact of disease volume on survival efficacy of triplet therapy for metastatic hormone-sensitive prostate cancer: a systematic review, meta-analysis, and network meta-analysis.

Int J Clin Oncol. 2024 Jun;29(6):716-725. doi: 10.1007/s10147-024-02485-4. Epub 2024 Apr 6.

Triplet Therapy: Entering the Metaverse of Metastatic Hormone-sensitive Prostate Cancer Treatment.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Triplet Therapy: Entering the Metaverse of Metastatic Hormone-sensitive Prostate Cancer Treatment.

作者信息

机构信息

出版信息

相似文献

引用本文的文献